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James Swanson, L. Eugene Arnold, Helena Kraemer, Lily Hechtman, Brooke 
Molina, Stephen Hinshaw, Benedetto Vitiello, Peter Jensen, Ken Steinhoff, Marc 
Lerner, Laurence Greenhill, Howard Abikoff, Karen Wells, Jeffery Epstein, Glen 
Elliott, Jeffrey Newcorn, Betsy Hoza, and Timothy Wigal. MTA Cooperative Group 
Objective: 
To review and provide details about the primary and secondary findings from the Multimodal 
Treatment study of ADHD (MTA) published during the past decade as three sets of articles. 
Method: 
In the second of a two part article, we provide additional background and detail required by the 
complexity of the MTA to address confusion and controversy about the findings outlined in part I (the 
Executive Summary). 
Results: 
We present details about the gold standard used to produce scientific evidence, the randomized 
clinical trial (RCT), which we applied to evaluate the long-term effects of two well-established unimodal 
treatments, Medication Management (MedMGT) and behavior therapy (Beh), the multimodal combination 
(Comb), and treatment “as usual” in the community (CC). For each of the first three assessment points 
defined by RCT methods and included in intent-to-treat analyses, we discuss our definition of evidence 
from the MTA, interpretation of the serial presentations of findings at each assessment point with a 
different definition of long-term varying from weeks to years, and qualification of the interim conclusions 
about long-term effects of treatments for ADHD based on many exploratory analyses described in 
additional published articles. 
Conclusions: 
Using a question and answer format, we discuss the possible clinical relevance of the MTA and 
present some practical suggestions based on current knowledge and uncertainties facing families, 
clinicians, and investigators regarding the long-term use of stimulant medication and behavioral therapy in 
the treatment of children with ADHD. (J. of Att. Dis. 2008; 12(1) 15-43) 
A. Introduction, Purpose, and Background for Part II (Supporting Details) 
1. Introduction 
Integrating the main findings of the series of three main reports (consisting of 8 articles) 
is not a simple task. Presenting the findings from multiple articles at each assessment points is 
complex, and linking these serially over the three assessment points magnifies the complexity. 
The interpretation and qualification of the main findings that incorporate information from the 
many additional articles (60 or more) further increases the complexity of this task. We thought a 
detail-heavy presentation might be distracting to some readers, but we anticipated that other 
readers would appreciate details about the evidence, interpretation, and qualification of the 
findings. Because of this, we decided to prepare a two-part article: in Part I (Executive 
Summary) we outlined issues without excessive detail, and here in Part II (Supporting Details) 
we will provide a plethora of details. 
2. Purpose 
Our purpose is to provide extensive (and perhaps excruciating) details necessary to 
explain why we believe that (a) the primary articles provide the main evidence from the MTA 
and must be narrowly focused, (b) the secondary articles provide broader interpretations that 
should be used to supplement but not replace this main evidence, and (c) the many additional 
articles (see Appendix) provide qualifications that should be considered exploratory, not definite, 
and used to generate new hypotheses to be tested in future research. In the final section on 
Clinical Implications, our purpose is to provide more details about future directions suggested by 
the interim findings of the MTA in a “question and answer” format. 
3. Background 
a. Genesis of the MTA 
The MTA was conceived at the beginning of an era (1990 to 2000) when the budget for 
NIH was increasing and public funding for large groundbreaking projects was feasible. This 
preceded the proliferation of industry funded studies that emerged in the late 1990s after the 
Food and Drug Modernization Act created financial incentives (the “pediatric exclusivity” rule) 
for pharmaceutical companies to evaluate medications in children (see DeVeaugh-Geiss et al., 
2006). The objectives of the MTA (see Richters et al., 1995) were described in a detailed 
Request for Applications (RFA) developed by the National Institute of Mental Health (NIMH) in 
the early 1990s. This RFA identified a need for long-term studies of established treatments for 
ADHD. Information from many short-term studies provided support for the clinical use of two 
treatment modalities, which we labeled medication management (MedMgt) and behavior therapy 
(Beh), but few long-term studies had been conducted of either of these or their combination. The 
RFA called for an ambitious long-term study to fill this gap. 
The review process of the proposals submitted in response to the RFA led to the selection 
of six sites for the study. Each of the proposals had a different specific design for the requested 
prospective study of long-term effects of treatments of ADHD, so it was necessary to develop 
consensus among the investigators from the multiple sites and the NIMH staff leading this 
initiative, which we called the MTA Cooperative Group. Our initial task was to develop a 
common protocol for the MTA. The evolution of the design and methods of the MTA were 
described in the initial publications by the MTA Cooperative Group in the late 1990s about the 
medication algorithm (Greenhill et al., 1996), the design (Arnold et al., 1997a, 1997b), and the 
assessment battery (Hinshaw et al., 1997), and later about the psychosocial treatments (Wells et 
al., 2000a, 2000b). 
b. Design and Analysis Framework for the MTA 
Early in the design process, we embraced the logic and methodology of the gold standard 
(see Kraemer & Robinson, 2005) for evidence-based medicine—the randomized clinical trial 
(RCT). As described by Gibbons et al. (1993), this requires that participants be randomly 
assigned to the treatment conditions to ensure the formation of groups would not be biased by 
preferences of those providing or receiving the treatments or by other factors that may operate 
intentionally or unintentionally. If the sample size is large enough, randomization should produce 
groups that do not differ in any systematic way at the baseline assessment. As part of the design 
phase of the MTA, a statistical power analysis was used to estimate the required sample size (n = 
576 to provide 144 participants per treatment group). During the recruitment and enrollment 
phase, the sample size requirement was exceeded by 3 cases, and n = 579 cases were diagnosed 
and randomized to the treatment conditions, with at least n = 24 per site assigned to each of the 4 
groups to allow for tests of site by treatment interactions (see Kraemer and Robinson, 2005). The 
RCT approach dictates the use of intent-to-treat (ITT) analyses, in which all participants who are 
randomized are analyzed to evaluate the effects of the assigned treatments, which may (and often 
do) differ from the actual treatment received by participants in the study. The actual treatment 
depends on whether the assigned treatments are accepted and implemented as intended. ITT 
analyses are intended to evaluate the recommendation for treatment and thus do not take actual 
treatment into account, although secondary analyses may do so to supplement the primary 
analyses. 
Also, early in the design process, we adopted a statistical method called based on random 
regression models (see Gibbons et al., 1993). This technique evaluates the change over time by 
estimating for each participant the intercept and slope of a regression equation relating outcome 
to time. By averaging these values across participants in each group, estimates are provided for 
the slope and intercept for the treatment. Based on random assignment, the treatment groups are 
not expected to differ on any measure obtained from the baseline assessment. If this is 
considered time = 0, then it defines the intercept of the regression equation for that measure. 
However, if the treatments result in differential change over time, then differences in the slope of 
the regression equation are expected. In the RCT approach, this type of regression analysis is 
applied to estimate relative rather than absolute effects of treatment (see Gibbons et al., 1993; 
Kraemer, Wilson, Fairburn, & Agras, 2002). Relative treatment effects are tested by contrasting 
slopes of regression lines describing outcome over time for the groups, which in our analyses 
could be accomplished by the evaluation of the treatment × time interaction. 
c. Number, Intensity, and Duration of Treatments 
The RFA directed us to select and contrast established treatments. In the initial meetings 
of the MTA Cooperative Group, a consensus was reached to evaluate two modalities of 
treatment, medication management (MedMgt) and behavior therapy (Beh), offered either alone 
or in combination (Comb). These treatment conditions were to be contrasted not only with each 
other but also with a fourth treatment condition that we called Community Comparison (CC). 
Because the short-term effectiveness of the two treatment modalities had been documented, we 
did not consider it ethical to insist on a true “no-treatment” control group in a long-term 
intervention study. Also, we thought it would be impractical to deliver a sham or placebo 
treatment over a long duration. Therefore, we decided to use a “treatment-as-usual” contrast 
group that we considered to be ecologically valid and consistent with the aims of our RCT. Some 
have agreed with us (see Barkley, 2000) but others have not (see Breggin, 2001). We used the 
word comparison instead of control because we expected participants in this group to receive a 
variety of treatments in the community, including treatment with stimulant medications. 
Decisions were required about the intensity of treatment and how long treatment should 
be provided. One of the first controversies our MTA Cooperative Group faced was about the 
intensity of treatment. We decided to provide state-of-the-art treatments, which made the MTA 
an efficacy study of very intensive treatments generally unavailable at the time rather than an 
effectiveness study of available treatments. A medication algorithm was developed for the MTA 
(see Greenhill et al., 1996) based on treatment with the most frequently prescribed stimulant 
medication, which in 1994 was immediate-release methylphenidate. To achieve coverage across 
the day, 3-times-a-day dosing was used, and to achieve coverage over the long term, medication 
was administered without weekend or summer holidays (i.e., 7 days a week, 365 days a year). A 
4-week double-blind titration was used to evaluate responses to a range of doses (from placebo 
to 20 mg) and to select the best per-administration dose for each participant (see Greenhill et al., 
2001). After titration, monthly clinic visits were scheduled for close monitoring by the MTA 
pharmacotherapists, with sufficient time allowed (i.e., 30 minutes) to discuss issues about 
attitude toward and adherence to the medication regime. The protocol required them to obtain 
information from the child’s teacher as well as from parents and from the child (in absence of the 
parents). Based on these sources, regular adjustments of dose were made (as needed) to maintain 
maximum benefit (see Vitiello et al., 2001). 
The MTA behavioral therapy was similarly intensive (see Wells et al., 2000a, 2000b). It 
consisted of three behavioral components: (a) a 27-session group parent training intervention 
supplemented with 8 individual sessions during the 14-month treatment phase; (b) a school 
intervention spanning 2 school years and including teacher consultation and a trained 
paraprofessional aide in the classroom of every participant for 12 weeks; and (c) an 8-week 
Summer Treatment Program. The components were coordinated over the 14-month treatment 
phase by the same behavior therapist for each participant, who conducted both the parent training 
and teacher consultation components that were faded over time. 
Based on our review of the literature on pharmacological treatments (see Greenhill et al., 
1996), we expected that in most cases the medication management delivered according to 
clinical practices in the community (i.e., number of clinic visits, doses of medication evaluated, 
sources of information about responses to treatment, etc.) would vary, but on the average we 
expected this treatment-as-usual would be less intensive than in our state-of-the-art medication 
management according to the MTA medication algorithm. Based on our review of the literature 
on psychosocial treatments (see Wells et al., 2009), we also expected that behavior therapy 
would not be generally available in the community, but if it were available, we expected the 
intensity of this treatment-as-usual would vary, too. As with medication, we expected on the 
average this would be less than in our state-of-the-art MTA behavioral algorithm. Based on the 
expectation of varying percentage of participants receiving treatment and varying intensities of 
those treatments in the communities where the study was to be implemented, we realized that the 
CC group might have greater variance on the outcome measures sensitive to treatment effects. 
This is a common assumption about treatment-as-usual compared to treatment-by-protocol, 
which has implications for the statistical comparisons that include this group (see NIH 
Conference on Considering Usual Medical Care in Clinical Trial Design, 2005). If the variance 
of the CC group were greater than the other groups, this could adversely affect statistical 
comparisons involving this group: For a given difference between average outcome for the CC 
and another group, the statistical significance would be reduced, unless a large sample was used 
to compensate for the hypothesized larger variance. (In fact, the variances for the most sensitive 
outcome measures, ADHD symptom ratings, were not larger in the CC group compared to the 
other groups [see Swanson, 2005]). 
During the design phase we had to set the length of our treatment period and the timing 
of our assessments. We expected the effects of one modality (treatment with medication) to 
emerge more rapidly than effects of the other modality (treatment with behavior therapy), and 
therefore we expected that the relative effects—the differences in outcome for the two treatment 
modalities— would vary over time. We decided that the most critical comparison would be at the 
end of the treatment phase, which we wanted to be as long as possible. Although we initially 
hoped to extend active treatment for 2 years, we were limited by the available budget for the 
MTA. Thus, we set the duration of treatment to be slightly over a year (14 months) to cover 2 
school years and the summer between them (see Wells et al., 2000). To address interim changes 
in symptoms and impairment, we scheduled 2 assessments at 3 months and 9 months after 
baseline, in addition to the end-of-treatment assessment at 14 months after baseline. 
d. Randomization and Selection Bias 
All children in the MTA met the same entry criteria (which included confirmation of a 
diagnosis of ADHD-Combined Type), but there was variation across these cases in severity of 
the symptoms of ADHD, presence of comorbid disorders, family characteristics, and many other 
factors. The process of randomization provides an unbiased assignment of participants to the 
treatments and thus protects against confounding these or others characteristics with the 
treatment conditions (see Gibbons et al., 1993). The general concern is that treatment determined 
by choice (of the clinician or the participant) might result in the tendency for the more severely 
affected cases to receive one type of treatment (e.g., stimulant medication) and the less severely 
affected cases another type of treatment (e.g., behavior therapy). When this occurs, the group 
choosing the preferred treatment (even if it is more effective) may have worse outcomes than the 
group that received the less preferred treatment, because groups determined by choice rather than 
randomization may differ in severity from the start—leading to different outcomes over time. In 
short, random assignment protects against an effect known as the intervention-selection bias 
(e.g., the most severely affected receiving the most intensive treatment, leading to an apparent 
association of such treatment with the worst outcome). 
The randomly assigned treatment may differ from the actual treatment received by 
participants, because acceptance of assigned treatment could be rejected and adherence to the 
recommended treatment regimes could be low. However, in RCT methodology, the ITT 
principle dictates that the analyses compare participants on the basis of their assigned groups 
regardless of adherence. Based on this, we adopted a strict rule for evaluating the participants 
who entered the study (“once randomized, always analyzed”). There was no switching of groups 
even if a participant switched treatments (e.g., if a participant assigned to the Comb group 
accepted the Beh component but refused the MedMgt component, in the ITT analysis the 
participant was retained in the Comb group and was not switched to the Beh group even though 
that was the actual treatment received). Thus, ITT analyses evaluate the recommended treatment 
rather than the actual treatment received. 
The ITT principle does not preclude observing actual treatment and using this 
information in secondary analyses. Of course, the secondary analyses of self-selected subgroups 
(e.g., based on acceptance and participation) are not protected by randomization from 
confounding effects of known or unknown factors that might be correlated with subgroup 
membership. However, these analyses are important to evaluate another potential selection bias 
that may operate in a RCT, which may be called the participation-selection bias (see Marcus & 
Gibbons, 2001). A participation-selection bias may result in an underestimate of the effect of a 
treatment in an ITT analysis when not all participants assigned the treatment actually receive it. 
We developed the Services for Children and Adolescents–Parent Interview (SCAPI) to track 
information about the actual treatment received, based on participant choice and ability to obtain 
services in the community (see Hoagwood et al., 2004; Jensen et al., 2000). We used the 
information from the SCAPI at each assessment point to establish patterns of medication use 
(i.e., consistently treated or inconsistently treated, never treated or newly treated, stopping 
treatment or starting treatment, etc.). These patterns defined naturalistic subgroups of 
participants, which were used in secondary analyses to supplement (but not replace) the primary 
analyses. 
e. Multiple Outcome Measures 
An important decision during the design process concerned the choice of outcome 
measures to be evaluated and tested in specific a priori hypotheses. Some members of the MTA 
cooperative group were proponents of a single global outcome measure, whereas others preferred 
multiple outcome measures from the large assessment battery (see Hinshaw et al., 1997) to 
evaluate differential impact of the treatment conditions on various outcome domains. Indeed, 
because ADHD symptoms per se may not be the best predictors of ultimate outcome, we decided 
to use multiple outcome measures, even though this procedure required adjustment for multiple 
comparisons in analyses of outcome to protect against false positive effects. At each assessment 
point, our plan was to repeat the full assessment battery with multiple measures from multiple 
methods of assessment and multiple sources of information. In the complete set of measures we 
expected redundancy, so we planned to use data reduction methods to determine a smaller set 
from different sources (e.g., parent, teacher, and child ratings) and various domains (e.g., ADHD 
and non-ADHD symptom domains, areas of functional impairment). 
For statistical evaluation of treatment effects, the convention is to set a significance level 
(e.g., p < .05) to limit false positive findings. To maintain this level of significance in the face of 
multiple comparisons, an adjustment of the significance level is necessary to keep the overall 
chance of a false positive at p < .05. A common correction called the Bonferroni adjustment is 
made simply by dividing the significance level by the number of comparisons. We were aware 
that the use of multiple outcome measures would result in a more stringent significance level for 
each of the statistical tests than if we used just one outcome measure. However, the complexity 
of ADHD and the importance of considering multiple domains of impairment as well as 
symptoms dictated our decision to use multiple outcome measures. This clearly contributed to 
confusion and controversy, which likely would have been much less had we specified one 
outcome measure as primary and explicitly considered all other uncorrelated outcome measures 
as secondary to merely elucidate the results on the primary. 
For the initial evaluation of long-term effects, our procedures identified six distinct 
domains—ADHD symptoms, oppositional/aggressive symptoms, internalizing symptoms, social 
skills, parent-child interactions, and academic achievement—with a total of 19 marker outcome 
measures (MTA Cooperative Group, 1999a). This provided the basis for adjustment of the 
significance level of the MTA (p  .05) by domain (.05/6) or by measure (.05/19) or in a 
sequential analysis by some combination of the domains and measures (see below). 
f. Multiple Comparisons 
As part of the design phase of the MTA, we formulated primary questions based on 
comparisons of any two treatment conditions in terms of change in outcome measures over time. 
Thus, we evaluated the effects of the four randomly assigned treatment conditions (average slope 
of the regression curves) compared to each other (i.e., relative effects) rather than the absolute 
effects compared to a no-treatment or placebo control condition that was not used in the MTA. 
With four treatment groups there are six paired-comparisons. Power analyses were 
performed taking the multiple sites into consideration (see Kraemer & Jackson, 2005). Under the 
assumptions of an effect size = 0.4 and power = 0.81, 24 participants per treatment per site (a 
total of 144 per treatment across sites) were required for the six possible comparisons of any two 
treatment conditions on the primary outcome measure of overall rating of ADHD core symptoms 
(see MTA Cooperative Group, 1999a). We organized these into three sets, with some directional 
hypotheses evaluated by one-tailed tests (denoted by “<” or “>”) and nondirectional hypotheses 
evaluated by two-tailed tests (denoted by “-”). The cutoff for statistical significance is more 
stringent for a two-tailed than a one-tailed test. The first set consisted of a nondirectional 
comparison of the unimodal treatments (MedMgt - Beh). The second set consisted of two tests 
based on directional comparisons of multimodal treatment to each of the unimodal treatments, 
with the expectation of multimodal superiority (Comb > MedMgt and Comb > Beh). The third 
set consisted of three directional comparisons of community treatment (treatment-as-usual) to the 
other treatments provided by MTA staff (treatment-by-protocol). Our treatment-as-usual 
condition (CC) was expected to be inferior to each treatment-by-protocol condition (CC < Comb, 
CC < MedMgt, and CC < Beh). 
Even though there are six possible pairwise comparisons for the four groups, only three 
comparisons can be used that will be statistically independent of each other. It is possible to 
construct several different sets of three contrasts that will be independent using the method called 
orthogonal contrasts. One set was proposed by Swanson et al. (2001): (a) the MTA Medication 
Algorithm contrast by comparing the average of two groups, both including the MTA method of 
intensive medication management as a component of the assigned treatment, to the average of 
the other two groups [(Comb + MedMgt) > (Beh + CC)]; (b) the Multimodal Superiority contrast 
that was the same as one of the pairwise comparisons (Comb > MedMgt); and (c) the 
Psychosocial Substitution contrast by comparing the generally unavailable intensive behavioral 
treatment of the MTA to generally available community standard treatment that in most cases 
included stimulant medication (Beh > CC). 
g. Adjustment for Significance Level 
In the primary analyses at the end of treatment (MTA Cooperative Group, 1999a), we 
initially planned to evaluate the overall rating of ADHD core symptoms as the primary outcome 
measure, and for the method of multiple comparisons this would require dividing the 
significance level by the number of comparisons (.05/6 = 0.008). But, to make 6 comparisons for 
19 outcome measures, the significance level should be divided by their product [e.g., .05/ (19 × 
6)]. This would require a drastic adjustment of the significance level from p < .05 to p < .05/114 
= .0004. However, we decided to perform sequential tests to justify a less severe adjustment. 
First, within each domain we adjusted our significance level based on the number of outcome 
measures within that domain (e.g., for the five outcome measures in the ADHD symptom 
domain, our adjustment was .05/5 = .01). Second, the six multiple comparisons for a given 
measure within a domain were made only if the omnibus test of the treatment × time interaction 
was significant, and for these the omnibus-adjusted significance level was further adjusted by 
dividing by 6 (i.e., for any significant measure within the ADHD domain, .01/6 = .002). These 
adjustments yielded significance levels of p < .002 to p < .004, depending on the number of 
measures within each domain (see MTA Cooperative Group, 1999a). 
h. Multiple Definitions of Long-Term 
The fundamental purpose of the MTA was to evaluate long-term effects of treatment. In 
the early 1990s a large literature existed that documented clear short-term beneficial effects (i.e., 
reduction of severity of ADHD symptoms) of stimulant medication and behavior therapy. The 
MTA started with documentation of short-term effects as it unfolded in a prospective fashion to 
evaluate long-term effects. The short-term effects of MedMgt were evaluated in a double-blind 
30-day titration trial, which verified beneficial effects manifested by reduction of ADHD 
symptoms and related behaviors on the first day, during the first week, and over the first month 
of treatment (Greenhill et al., 2001). Intermediate effects were estimated from the assessments at 
3 months and 9 months after randomization (see Arnold et al., 2004). Also, intermediate effects 
were provided by a comparison of two treatments (Comb and Beh) during the implementation of 
one component of behavior therapy, the summer treatment program (Pelham et al., 2000). 
However, the fundamental purpose of the MTA was to assess the long-term effects of treatment, 
and for the initial end-of-treatment analyses in our RCT design, long-term was defined by ITT 
analyses of outcomes at the 14-month assessment. 
i. A Priori and Post Hoc Tests 
As in any area of investigation in science or medicine, the rigorous evaluation of a 
limited number of primary hypotheses in the MTA will leave many additional questions 
unaddressed. For example, at the initiation of the MTA, the hypothesis of stimulant-related 
growth suppression had been discounted (see Roche et al., 1979). Based on this literature, we did 
not include the hypothesis of growth suppression in our specific aims, and we had not listed 
growth suppression as a possible side-effect of treatment with medication in our consent forms. 
Before our initial findings were published, an additional influential study (Spencer et al., 1996) 
and another comprehensive review (NIH Consensus Conference on ADHD, 1998) discounted the 
hypothesis of stimulant-related growth suppression. Based on this, we did not include an 
evaluation of growth in our initial publication of findings at the end of the treatment phase (MTA 
Cooperative Group, 1999a). However, because we included the measurement of physical size at 
each assessment, we conducted the post hoc evaluation of the growth suppression. This analysis 
was not published until we reported the findings from our first follow-up evaluation (see MTA 
Cooperative Group, 2004b). 
For post hoc tests, both false positive results (related to the many statistical comparisons) 
and false negative results (related to size of detectable effects given reduced sample size of 
various subgroups) are expected, so these supplemental reports should not be used to accept or 
dismiss any specific hypothesis with firmness. The findings of post hoc tests should be 
interpreted with caution and with full recognition that they generate the next set of hypotheses to 
consider for rigorous evaluation in future randomized clinical trials (see Kraemer et al., 2002). 
B. Publications at the End of Treatment (MTA Cooperative Group, 1999a, 1999b) 
1. Evidence: ITT Analyses 
Our use of multiple outcome measures and multiple comparisons introduced a level of 
complexity that has surely contributed to controversies related to the findings from the MTA. We 
do not have a single test, or even a few tests, to characterize the findings of the MTA. Instead, in 
our primary analyses at the end of treatment (MTA Cooperative Group, 1999a), the omnibus test 
of a significant interaction of treatment condition with time was significant for 10 of the 19 
outcome measures (4 were from the ADHD symptom domain and 6 were from the other 
domains). Therefore, we performed 10 × 6 = 60 paired-comparisons of the treatment conditions, 
and 23 of these were significant at the adjusted significance levels (see MTA Cooperative Group, 
1999a, Table 5). 
For the contrast of unimodal treatments (MedMgt - Beh), we reported that MedMgt was 
better than Beh on 3 of the 10 outcome measures that had revealed significance in the omnibus 
tests, and all of these were ratings of ADHD symptom severity. For the multimodal treatment 
comparisons (Comb > MedMgt and Comb > Beh), we reported that Comb was not better than 
MedMgt on any of the 10 outcome measures but was better than Beh on 6 of them (and 3 of 
these were ratings of ADHD symptom severity). For the comparisons to community treatment 
(CC < Comb, CC < MedMgt, and CC < Beh), we reported that, of the 10 outcome measure, CC 
was worse than Comb on 9, MedMgt on 5, and Beh on 0. 
The synthesis of these analyses reveals two key findings (see MTA Cooperative Group, 
1999a). First, assignment to pharmacological treatment according to the intensive MTA 
medication algorithm (MedMgt) produced larger benefits (i.e., reduction in ratings of ADHD 
symptom severity) than long-term psychosocial treatment according to the intensive MTA 
behavior therapy algorithm (Beh). Second, relative benefit from assignment to the multimodal 
combination (Comb) was not significantly greater than to the MTA medication algorithm alone. 
2. Interpretation: Moderator and Mediator Analyses 
Kraemer et al. (2002) and Hinshaw (2007) provide cogent discussions of moderator and 
mediator analyses in the context of clinical trials. The secondary analyses (MTA Cooperative 
Group, 1999b) addressed some of these issues by performing moderator analyses of 
heterogeneity within the randomized groups (e.g., subgroup analyses based on measures from the 
baseline assessment battery obtained prior to randomization) and mediator analyses of variables 
related to treatment implementation (e.g., actual treatment related to acceptance of and adherence 
to the MTA protocols). 
In the secondary article at the end of treatment (MTA Cooperative Group, 1999b), 
moderator analyses were conducted for five variables (sex, prior medication status, comorbid 
oppositional defiant or conduct disorder, comorbid anxiety disorder, welfare status) and for one 
mediator variable (acceptance and attendance related to treatment sessions deemed to be as-
intended or below-intended). For each of these, random regression analyses were performed for 
14 of the 19 outcome measures. This required 84 analyses, but these were considered exploratory 
analyses for generating hypotheses for future research so the Bonferroni adjustment to the 
significance level was not used. 
The moderator analysis suggested that the pattern of treatment response (i.e., statistical 
significance on more than one outcome measure) differed for subgroups defined by comorbid 
anxiety disorders (present or not) and family income (public assistance or not). In the subgroup 
of the ADHD participants with anxiety disorders at baseline (34% of the sample), Beh was not 
significantly worse than either MedMgt or Comb on any outcome measure and was significantly 
better than CC for three outcome measures (parent rating ratings of ADHD symptoms and 
internalizing social skills and child interview of anxiety symptoms). In the subgroup on public 
assistance, the relative effect of Comb was superior to all other treatments for two outcome 
measures (teacher ratings of total social skills and parent ratings of personal closeness with the 
child). 
For mediator analyses, we identified subgroups with as-intended treatment according to 
the MTA medication algorithm (78%) and the behavior therapy algorithm (63%). Mediator 
analysis revealed that for the medication component in the MedMgt and Comb treatment 
conditions, the subgroups with as-intended treatment manifested a greater response (reduction in 
ADHD symptoms over time) than the subgroup with below-intended participation in the 
MedMgt group. Interestingly, for the behavior therapy component of the Beh and Comb 
treatment conditions, the mediator analyses indicated that the as-intended and below-intended 
subgroups did not differ. Thus, the lower acceptance and attendance of the Beh than the MedMgt 
component did not account for the significant difference between these two unimodal treatment 
conditions in the primary ITT analyses. The acceptance and attendance measures may have been 
insufficient to serve as mediator variables, and other factors (actual parent and teacher 
implementation of behavioral programs) that likely would have been superior for this purpose 
but were not assessed and could not be evaluated as mediators. 
In the secondary article (MTA Cooperative Group, 1999b), in addition to the mediator 
analysis of acceptance and attendance related to the MTA treatment algorithms, these variations 
of medication use in the community were addressed. The CC subgroup that received treatment 
with medication in the community (68% of the CC participants) had better outcome than the 
subgroup that did not. Greenhill et al. (submitted) documented that for the CC group, medication 
was prescribed at lower doses, the frequency of dosing was less (usually 2 rather than 3 times a 
day) and was monitored with fewer office visits (roughly 9 minutes every 5-6 months vs. 30 
minutes every month), and direct input from the child’s teacher was not usually obtained. The 
medication-treated subgroup of the CC group had better outcome than the nonmedication 
subgroup, which was similar to the outcome of the Beh group but was worse that the outcome of 
the MedMgt group. This pattern suggests that the intensive Beh treatment of the MTA and 
medication treatment-as-usual may have about the same effectiveness (although we should only 
assert that we could not document a statistical difference), whereas more intensive treatment 
according to the MTA medication algorithm may have greater efficacy than treatment-as-usual 
with medication by clinicians in the community. 
3. Qualification: Additional Exploratory Analyses 
a. Additional Moderator Analyses 
Jensen et al. (2001a, 2001b) reported that children with ADHD plus anxiety 
comorbidities (but not disruptive comorbidities) did relatively well with Beh, but children with 
ADHD plus both anxiety and disruptive comorbidities had poor outcomes unless they received 
Comb. For ADHD cases with the double comorbidity of disruptive behavior (e.g., oppositional 
or conduct disorder) and internalizing disorders (e.g., anxiety or depression), Comb was the only 
treatment condition leading to meaningful gains. Thus, in the MTA trial, some participants were 
relatively refractory to the intensive medication management provided by the MTA, revealing 
that additional components of treatment may be necessary to benefit the cases with the greatest 
severity of ADHD symptoms and adversity in life. 
Owens et al. (2003) reported that even though the MTA medication algorithm was quite 
effective overall for improving ADHD and ODD symptoms in the sample, it was notably less 
effective for children who entered the study with severe symptom levels of ADHD, for those 
whose primary caregivers had even mild levels of depression, and for those with subaverage IQ 
score. 
Arnold et al. (2003) performed an analysis of ethnicity and reported a significant 
interaction for this moderator. Caucasians showed no advantage of Comb over MedMgt, but 
pooled minorities did, with an effect size of 0.36. 
Hechtman et al. (2005) evaluated another interesting and important outcome measure 
(e.g., presence of comorbid disorders), and reported that Comb, but not MedMgt, was 
statistically superior to CC for reducing the persistence or development of comorbid 
oppositional-defiant and mood disorders. 
Santosh et al. (2005) performed a moderator analysis based on subgroups defined by the 
rediagnosis of the DSM-IV cases by applying criteria and guidelines for the ICD-10 diagnosis of 
Hyperkinetic Disorder (which requires greater pervasiveness of symptoms across home and 
school setting than the DSM-IV diagnosis of ADHD-Combined Type) using a well-developed 
algorithm (“Hypescheme”) to consolidate information from the assessment battery. Only 25% of 
the MTA cases with a DSM-IV diagnosis of ADHD Combined Type also received an ICD-10 
diagnosis of Hyperkinetic Disorder. In the subgroup with Hyperkinetic Disorder, the response to 
MedMgt was larger and the response to Beh was smaller than in the other subgroup, so the 
difference between MedMgt and Beh was very large. However, for the remaining 75% of the 
MTA cases, the difference between MedMgt and Beh was much smaller. The greater relative 
superiority of medication at the end of the 14-month treatment phase was suggested as evidence 
in support of the recommendation of medication as the first choice to initiate treatment in cases 
with Hyperkinetic Disorder. For those without the extreme level of pervasiveness of symptoms 
across domains and sources required for this diagnosis, Santosh et al. (2005) speculated that 
nonpharmacological treatment may be preferred as the first choice for treatment, with a provision 
to add medication later if necessary. This provided some justification for a second option for 
staging treatment components. In less severe cases, Beh might be considered as a first choice 
when cultural or national differences (see Taylor, 1999) provide a context of low preference for 
medication. 
We also explored difference among subgroups in responses to behavior therapy. Hinshaw 
et al. (2000) reported that improvements in parents’ negative/ineffective discipline helped to 
explain major improvements in both school-based social skills and disruptive behavior for youth 
randomly assigned to Comb. For families who showed meaningful reductions in 
negative/ineffective discipline styles during the course of the trial, only Comb led to high rates of 
normalized functioning by the end of 14 months of active intervention. In qualitative analysis of 
a cutoff based on symptom severity intended to denote successful treatment, the percentage of 
cases considered to be successfully treated in the Comb group (68%) was significantly higher 
than in the MedMgt group (56%). 
Thus, both the percentage of participants treated with the MTA medication algorithm and 
the behavioral algorithm and the characteristics of the treatment regimes, varied across the 
assigned groups and within each treatment group (i.e., in some identifiable subgroups). This 
complexity contributed to controversy about who was treated in the various subgroups and how 
they were treated with stimulant medication and with behavior therapy. These selection and 
implementation factors may affect outcome substantially, but could not be adequately evaluated 
in the MTA. 
b. Multiple Comparisons Across Outcome Domains 
The decision to use multiple outcome measures appeared to be justified, because these 
analyses suggested some key differences across domains. With so many tests, we resorted to 
discussion and interpretation of the pattern of significant effects in our attempts to understand the 
complexity of the findings. In order to summarize the six paired comparisons within the 10 
significant outcome variables, a count of significant effects within the ADHD and non-ADHD 
symptoms domains is informative. 
Within the four significant outcome measures in the ADHD symptom domain (parent and 
teacher ratings of inattention and hyperactivity/impulsivity symptoms), four of the six pairwise 
comparisons (MedMgt – Beh, Comb > Beh, CC < Comb, and CC < MedMgt) were significant 
for almost all (either three or four) of these four measures. Yet for the other two comparisons 
(Comb > MedMgt or CC < Beh), pairwise comparisons were not significant for any of these four 
outcome measures. This pattern led to controversy regarding the necessity of behavioral 
treatment for ADHD symptoms. Indeed, the lack of significance for these two contrasts—Comb 
> MedMgt (multimodal treatment vs. medication alone) and the CC < Beh (treatment as usual vs. 
intensive, muticomponent behavioral treatment)— was interpreted to mean that addition of 
behavioral treatment to medication treatment was not better than medication alone, and that 
intensive, multicomponent behavioral treatment was not better than treatment as usual in the 
community (which involved medication in about two thirds of the MTA cases assigned to CC). 
For the five domains of outcome beyond ADHD symptoms per se, another systematic 
pattern was obtained: All of the significant paired comparisons involved the Comb treatment. 
Comb was better than CC for 5 of the 10 outcome measures (oppositional/aggressive parent and 
teacher ratings, internalizing parent ratings, social skills teacher ratings, and parent-child power 
assertion), and Comb was better than Beh for 2 of the 10 outcome measures 
(oppositional/aggression and internalizing parent ratings). Interestingly, except for parent-rated 
ODD/aggression, MedMgt was not superior to CC or Beh on any of these outcome measures 
from the non-ADHD domains, whereas Comb was better than CC on most of the outcome 
measures and better than Beh on some of them. (It is relevant to note that this pattern was not 
unique to the non-ADHD domains: as described above, Comb was better than CC on all four of 
the measures from the ADHD domain and Comb was better than Beh on three of the four ADHD 
measures, and these effects were larger than for any non-ADHD domain.) In addition, in a 
detailed analysis of objectively coded parent-child interactions using trained, blind observers, 
Comb was better than MedMgt (and CC) on positive constructive parenting (Wells et al., 2006), 
which provided additional evidence of relative benefits from adding behavioral intervention to 
medication management. 
c. Post Hoc Single Composite Outcome Measures 
To further consider the hypothesis of multimodal superiority (which was not significant 
in the main analyses of multiple outcome measures), we explored the use of a single outcome 
measure in two related but not identical approaches. Swanson et al. (2001) used a narrow 
composite of just two domains (the ADHD and ODD ratings by parents and teachers). The 
combination of ratings across symptom domains (inattention, hyperactivity, and ODD) and 
information sources (parents and teachers) produced a composite measure with about a 40% 
reduction in variance for each treatment group. For the multimodal comparison, Comb was 
significantly better than MedMgt (p < .05) with an effect size of 0.26. Conners et al. (2001) used 
a broad composite that combined standardized scores for the ADHD and ODD domains plus 
many others (e.g., internalizing symptoms, social skills, academic performance, and parenting 
style at home). On this composite, the Comb versus MedMgt comparison was statistically 
significance (p < .012) with an effect size of 0.28. 
Thus, in these two articles, we reported that Comb was statistically superior to MedMgt 
in analyses of a composite score, even though this critical multimodal superiority comparison 
was not significant for any of the individual outcome measures included in the composites. Two 
methodological explanations clarify this quirk: (a) as expected from the Spearman-Brown 
principle, the composite of multiple measures increased the precision of measurement by 
reducing the treatment group standard deviations for the single outcome measure compared to 
the separate measures (and thus increased effect size and statistical significance); and (b) the use 
of a single outcome measure rather than multiple outcomes required less severe adjustment of 
significance levels for the statistical tests performed (and thus a smaller F or t value would 
exceed the cutoff for statistical significance). 
The findings from these two supplementary reports contrast with the findings of primary 
analyses because they suggest superiority of multimodal treatment whereas the primary analyses 
did not. These two reports may have generated some confusion despite their consistency, 
because they offer different reasons for using a composite measure. Swanson et al. (2001) 
emphasized a statistical reason: The combination of domains and sources increases precision, so 
that for a single outcome measure the effect size was increased (e.g., from less than 0.16 to 0.26). 
Conners et al. (2001) suggested that the small effects across non-ADHD outcome measures (all 
with very small individual effect sizes) combine with the ADHD outcome measures (with the 
largest individual effect sizes across all measures) to yield significant difference between Comb 
and MedMgt. 
Also, different methods were used for comparing the treatments. Conners et al. (2001) 
continued with the pairwise comparisons used in the primary analyses (see MTA Cooperative 
Group, 1999a), whereas Swanson et al. (2001) adopted the orthogonal comparison approach. For 
the pairwise comparisons, Conners et al. (2001) used the Bonferonni adjustments to the 
significance level (p < .05/6 = .0083), but for the orthogonal comparisons that decompose the 
overall effect of treatment into nonoverlapping components, Swanson et al. (2001) used the 
unadjusted significance level (p < .05). For four treatment conditions, there are six possible 
pairwise comparisons, but only three independent comparisons (some of which may contrast 
multiple treatments) can be made. The three comparisons were proposed by Swanson et al. 
(2001) for exploratory analyses to make the following contrasts: (a) the MTA Medication 
Algorithm contrast by comparing the average of two groups with this method of intensive 
medication management as a component of assigned treatment to the average of the other two 
groups [(Comb + MedMgt) – (Beh + CC)]; (b) the Multimodal Superiority contrast that was the 
same as one of the pairwise comparisons (Comb > MedMgt); and (c) the Psychosocial 
Substitution contrast by comparing the generally unavailable intensive behavioral treatment in 
relation to generally available community standard treatment that in most cases included 
stimulant medication (Beh – CC). 
d. Evaluation of Non-ADHD Outcome Measures 
In the primary article (MTA Cooperative Group, 1999a), exploratory secondary analyses 
suggested that multimodal treatment may be superior to medication alone in some subgroups, but 
with our specific tests of hypotheses in our design we failed to detect the difference. On the 
multiple statistical tests performed, comparisons of both Comb and MedMgt to the CC condition 
produced different patterns of significance across the outcome domains not reflecting ADHD 
symptoms: Comb but not MedMgt was superior to CC for reading achievement, parent-rated 
oppositional- defiant behavior, parent-rated internalizing symptoms, teacher-rated social skills, 
parent-child relations, and reduction in comorbidity. On an objective measure of parenting, 
Comb was superior to MedMgt. These exploratory analyses suggest that in the MTA design, if 
we had emphasized outcome measures that go beyond assessment of ADHD symptoms we may 
have revealed additional evidence in favor of multimodal superiority. Even though the difference 
was larger for ADHD symptoms than for any of the non-ADHD symptom measures, the analyses 
of patterns of effects suggests that the lack of significant differences for comparisons of MedMgt 
versus CC was more frequent in the non-ADHD outcome measures compared to the measures 
based on ADHD symptoms. 
e. Acceptance of the Null Hypothesis 
It is important to note that acceptance of null hypotheses is not recommended. We 
believe that much of the confusion about the findings from the MTA comes from the incorrect 
interpretation of non-significant results as proofs of the null hypothesis of equivalence. As our 
statistical consultants warned, “The absence of evidence should not be taken as evidence of 
absence.” Instead, in addition to the test of a priori hypotheses (e.g., in the end-of-treatment 
analyses, the planned tests of treatment × time interactions followed by the six paired-
comparisons of the four groups), post hoc exploratory analyses are recommended to consider 
possible methodological weaknesses in current research and to direct improvements for future 
research (Kraemer et al., 2002). For example, we used moderator analyses to address the issue of 
relative benefit of Comb over MedMgt (the multimodal superiority effect) and Beh over CC (the 
psychosocial substitution effect). In the secondary article (MTA Cooperative Group, 1999b), we 
evaluated outcomes in subgroups with and without comorbid anxiety disorder, and in the 
subgroup with comorbid anxiety, Beh was superior to CC and was not inferior to MedMgt. This 
supported our decision not to accept the null hypothesis that intensive Beh treatment of the MTA 
was no different than treatment as usual, which could lead us or others to discard an effective 
treatment that might be effective. Instead, as recommended by Kraemer et al. (2002), we 
calculated effect size and interpreted the estimated magnitude of the observed effects in 
secondary analyses, which suggested some stratification factors that might be considered in a 
future RCT. 
In all of these analyses in the primary, secondary, and additional articles, the effect size 
for multimodal superiority—the magnitude of the relative superiority of Comb over MedMgt—
was not large (i.e., from 0.25 to 0.28). However, this estimated magnitude of effect suggests a 
new hypothesis that could be tested in a future study. For example, the pattern of significant 
effects in the multiple comparisons (described above) and the estimates of effect sizes suggest 
that the MedMgt falls between the extremes of Comb and CC but closer to Comb than to CC. 
With a different design and greater statistical power, the comparisons of the MedMgt group to 
one or both of these extreme groups might be statistically significant. 
The secondary and additional articles about the effects at the end of the treatment phase 
of the MTA all address post hoc hypotheses that are interesting, and together the findings may 
even seem compelling, but they do not have the same standing as the findings based on the a 
priori hypotheses that were specified by the design of the MTA. By the rules for evidence-based 
medicine, the positive (i.e., statistically significant) results of the primary ITT analyses of a RCT 
should take precedence. Unfortunately, in some instances, interpretations of interesting but 
complex findings from the many exploratory analyses of the MTA may have resulted in 
confusion and controversy rather than (as intended) clarification of the primary findings of the 
MTA. 
f. Commentaries on the End of Treatment Findings 
The initial commentaries and critiques were based on opinions about design 
characteristics of the MTA. The commentary that accompanied the initial reports (Taylor, 1999) 
addressed the usual two areas by considering strength (large sample, good design, successful 
implementation, and sophisticated analyses) and limitation (the definition of long-term, the 
nature of treatment-as-usual, and tests of null hypotheses). In addition this commentary 
addressed the interesting issue of dependence on cultural context for definition of treatment-as-
usual (which may be similar to MedMgt in the United States but similar to Beh in the United 
Kingdom) and for multimodal superiority (which may be defined by Comb vs. MedMgt in the 
United States but Comb vs. Beh in the United Kingdom). We agreed with all of these percipient 
comments. 
Commentary by Boyle (1999) focused on limitations that we considered to be strengths. 
For example, he criticized the use of randomization on the grounds that it may have restricted 
entry into the study and rendered the sample atypical of clinical practice) and high-intensity 
treatments (which were not generally available and thus lacked ecological validity). 
Commentary by Jensen (1999) explained the rationale behind the use of the RCT 
methods to conduct an efficacy study of intensive interventions rather than an effectiveness study 
of available interventions, and the feasibility of implementing components of the MTA 
algorithms to improve treatment-as-usual. He also focused on misrepresentations and 
mischaracterizations of the MTA, including the claims that the Beh component was ineffective 
and that the Comb treatment was not superior to MedMgt. 
Commentary by Cunningham (1999) focused on the viability of the behavior therapy 
used in the MTA, the relative benefits of it compared to pharmacological treatment, and the 
possible advantages of combined treatment. He pointed out that secondary analyses will be 
required to address these questions in an adequate fashion. We agreed with these points, and 
since then we have provided many secondary analyses. 
Commentary by Pelham (1999) focused on aspects of the design that may have 
predisposed the MTA in favor of pharmacological treatment (which reached highest intensity at 
the end of the 14-month treatment phase due to medication adjustments) over psychosocial 
treatment (which was faded at the end of the 14-month treatment phase). 
Commentary by Barkley (2000) focused on our lack of use of theory of the underlying 
deficit in ADHD (with an example of his own theory of “inhibition deficit”). He speculated this 
was the primary reason that “the Beh treatment was ineffective.” In response to this commentary, 
Swanson et al. (2002) pointed out this interpretation was based on acceptance of the null 
hypothesis and confusion about the comparisons of outcomes over time in the regression analysis 
framework, which showed significant effects of time for all groups but relative differences in 
degree of improvement across the treatments. 
Breggin (2001) focused on the lack of a placebo control and weak effects based on blind 
observers and concluded that the evidence from the MTA did not justify a recommendation of 
medication as the “first line” treatment. This was followed by commentary by Klein (2001), who 
concluded that the evidence from the MTA did not justify a recommendation of multimodal 
treatment by adding Beh to MedMgt. In a response to this commentary, Jensen (2001) pointed 
out that these conclusions—based on the same findings—were polar opposites. 
Greene and Ablon (2001) focused on ecological validity of the MTA treatments, 
suggesting that the lack of tailoring of the behavioral treatments may have underestimated the 
effects of this modality in clinical settings. In response to this commentary, Wells (2001) 
addressed the problems involved in “tailoring” and the lack of effectiveness of tailoring 
treatments in other large trials., and Hoza (2001) related the treatments and outcomes of the 
MTA to prior studies of social, family and motivational processes. 
g. The Main Confusions and Controversies at the End of Treatment 
Why were the primary findings reported by the MTA Cooperative Group (1999a, 1999b) 
controversial? Based on the evidence at the end-of-treatment, the multimodal treatment did not 
provide significantly greater benefits than unimodal treatment with stimulant medication for any 
of the outcome measures. This pattern of outcome suggested that many children treated with the 
medication as prescribed by the MTA algorithm would not require the intensive behavioral 
interventions of the MTA to achieve the full effect of treatment. The assertion that intensive 
behavior therapy was ineffective was controversial. 
Some of the secondary and additional findings were intended to dispel confusion and 
resolve some controversies about the primary findings about the ineffectiveness of the Beh 
treatment, a conclusion that was based on the premature acceptance of the null hypothesis. We 
did not provide evidence of effectiveness of Beh treatment in general (i.e., in the primary 
analyses of the MTA), but moderator analyses suggested that for subgroups with certain 
characteristics Beh was more effective than for other subgroups. For example, analyses of 
moderators of treatment effects suggested that in the subgroup of children with ADHD and 
comorbid anxiety, the Beh treatment appeared to be particularly effective (and not ineffective as 
erroneously interpreted by some from the primary findings). Furthermore, when non-ADHD 
outcomes are considered, in socioeconomically disadvantaged families the Comb treatment was 
superior to MedMgt with respect to social skills (not equal as suggested in the primary analyses). 
These secondary analyses suggest that enhanced response to the Beh treatment may have 
occurred in some subgroups of participants. We did not focus our secondary analyses only to 
explore effects of the MTA behavioral algorithm. We also used secondary analyses to explore 
effects of the MTA medication algorithm. Mediator analyses suggested whether the participants 
accepted the assignment to treatments with medication or followed the MTA medication 
algorithm “as intended” affected long-term outcome, and analysis of the CC group suggested that 
the way community clinicians prescribed and monitor medication as also affects long-term 
outcome in this comparison group. 
Taken together, these supplementary analyses at the end of the 14-month treatment phase 
suggested that long-term relative effects of the different modalities of treatments may depend on 
who was treated (e.g., the characteristics of the subgroup—those with anxiety may have 
enhanced response to the Beh treatment), how they are treated (e.g., the nature of the 
pharmacologic protocol— those with more intensive monitoring and adjusting of dose may have 
enhanced response to treatment with stimulant medication), and what outcome measures were 
evaluated. Nonetheless, the implication that the Beh treatment was not a necessary component of 
treatment of ADHD was one of the most controversial aspects of the initial reports of the end-of-
treatment findings (MTA Cooperative Group, 1999a). 
C. Publications After the First Follow-Up (MTA Cooperative Group, 2004a, 2004b) 
1. Evidence: ITT Analyses 
At the first follow-up assessment, 10 months after the end of treatment by MTA 
protocols, recommendations were made and participants were left to obtain their own 
individualized treatment regimens. Despite this, ITT analyses were used again to evaluate the 
persistence of effects of the randomly assigned treatments (MTA Cooperative Group, 2004a). 
However, some changes in the analysis framework were made. 
First, while the initial definition of long-term in the MTA was just beyond a year (14 
months), the revised definition for longer term was now 2 years (24 months). Thus, in these 
analyses the evaluation of long-term focused on outcome 10 months after the end of our 
intensive treatment phase when interventions were delivered by the MTA protocols. Rather than 
evaluate regression equations for each group and compare slopes by testing the treatment × time 
interaction, analyses of the 24-month outcomes (with the baseline observations used as 
covariates) were performed to evaluate the persisting effects of assigned treatment at this follow-
up assessment. 
Second, a different method for making multiple comparisons was adopted. Benefiting 
from our previous experience, we switched from the pairwise comparison method to the 
orthogonal comparison method. The 3 orthogonal comparisons developed by Swanson et al. 
(2001) were adopted: (a) the MTA Medication Algorithm contrast, which compares the average 
of two groups assigned to this method for intensive medication management to the average of the 
other two groups [(Comb + MedMgt) – (Beh + CC)]; (b) the Multimodal Superiority contrast, 
which is the same as one of the pairwise comparisons (Comb > MedMgt); and (c) the 
Psychosocial Substitution contrast, that compares the generally unavailable intensive behavioral 
treatment to the generally available community standard treatment that in most cases included 
stimulant medication (Beh – CC). 
Third, in these follow-up analyses we changed the number of outcome measures from 14 
to 5, which imposed less stringent per-comparison alpha correction procedures. Instead of 
treating each source (parent and teacher) as a separate measure on ratings from the ADHD, 
ODD, and social skills domains, we treated source (rater) as a factor in the analysis. If the main 
effect of factor was not significant, then collapsing across the two levels allowed us to combine 
(averaged) the parallel ratings from the two sources and reduce the number of outcome 
measures. Also, based on the principle of parsimony, we refined the outcome domains, using 2 
domains that related to symptoms of psychiatric disorder (ADHD and ODD symptom ratings) 
and 3 domains related to functional impairments (Social Skills, Parental Discipline, and Reading 
Achievement). Together, these changes allowed for less stringent adjustment for multiple 
comparisons (p < .05/5 or p < .01). We first evaluated the overall effect of treatment on 24-
month outcome, and if this was statistically significant at p < .01, then we performed the 3 
orthogonal comparisons. 
In the primary analyses, the main effect of assigned treatments was significant for the 
ADHD (p = .0001) and ODD (p = .0019) domain measures, but not for the outcome measures of 
Social Skills (p = .06), Discipline (p = .05), or Reading (p = .38). The subsequent orthogonal 
comparisons for the two significant domains revealed that only the MTA Medication Algorithm 
effect (Comb + MedMgt – Beh + CC) was significant. To evaluate the magnitude of this 
significant effect at the 24-month follow-up, the effect size was contrasted with the effect size at 
the 14-month assessment. This showed that the magnitude of the relative superiority of the MTA 
medication algorithm was reduced by 50% from a medium effect size in the end-of-treatment 
analyses (0.6) to a small effect size in first follow-up analyses (0.3). 
We observed that between the 14-month and 24-month assessments, the MedMgt and 
Comb groups showed a slight increasing trend in symptom severity, whereas the Beh and CC 
groups remained constant. We performed mediator analyses to test whether this loss of relative 
advantage of the MTA Medication Algorithm could be attributed to current medication use. To 
accomplish this, we used the report of current medication use at the 24-month assessment point 
as a covariate. (Two definitions of current—anytime during the 10-month follow-up or during 
the 30 days before the 24-month assessment—were considered, but both produced the same 
effect.) The covariate was significant for the analysis of ADHD symptoms, indicating that 
current medication improved outcome at the 24-month assessment. However, even after 
adjustment for current medication use, the overall treatment effect and the MTA Medication 
Algorithm contrast remained highly significant. These findings suggest that after treatment was 
no longer provided or monitored by the MTA staff, choices about taking medication during the 
follow-up explained part but not all of persisting advantage of the MTA medication algorithm 
(MTA Cooperative Group, 2004a). 
2. Interpretation: Naturalistic Subgroup and Physical Growth Analyses 
a. Naturalistic Subgroups Based on Actual Treatment 
The secondary analyses of the first follow-up (MTA Cooperative Group, 2004b) 
extended the primary analyses by (a) evaluating patterns of actual treatment over time in 
“naturalistic subgroups” (rather than assigned treatment in the primary analyses) and (b) 
evaluating change in outcome between the 14-month and 24-month assessment points (rather 
than status at the 24-month assessment point as in the analyses reported in the primary article). 
Naturalistic subgroups were formed by considering medication status (Med or NoMed) at 
the end-of-treatment and first follow-up assessment points. We identified four subgroups defined 
by a pattern of consistent use (Med/Med) or nonuse (NoMed/NoMed) of medication at the 14-
month and 24-month assessment points, or a pattern of stopping (Med/NoMed) or starting 
medication (NoMed/Med) during the 10-month follow-up. In this initial method to establish 
naturalistic subgroups, we did not consider medication status of the participants before entering 
the MTA. (Later we realized that this may be important and attempted to evaluate this factor [see 
Swanson et al., 2007b].) Our operational rule for establishing medication status was whether 
medication was taken or not during the 30 days prior to the assessment point. Because all 
participants had a 30-day “wash-out” period without medication before the baseline assessment, 
we considered all participants to have the same status (NoMed) at the baseline assessment, even 
though about one third of the participants had a prior history of medication use. 
In short, these secondary ITT analyses suggested that the Comb and MedMgt groups 
manifested greater change than the Beh and CC groups, since they showed greater deterioration 
during the follow-up from the 14- to the 24-month assessment point. In these secondary analyses, 
we then added naturalistic subgroup membership as a mediator. After this adjustment, which 
accounted for the improvement in symptoms of ADHD in the subgroup that started medication 
and the deterioration in the subgroup that stopped medication, the effect of assigned treatment 
was no longer significant. In combination with the differential adherence to assigned treatments 
(i.e., more cases in the MedMgt and Comb groups stopped medication and more cases in the Beh 
and CC groups started medication), this implicated choice about medication use during the 10-
month follow-up as a factor that contributed to the 50% loss of relative superiority of the 
MedMgt and Comb over the Beh and CC groups (MTA Cooperative Group, 2004b). 
The different methods used for the primary analyses (absolute scores at the 24-month 
assessment point, with current medication as a mediating variable) and the secondary analyses 
(change scores from the 14-month to the 24-month assessment points, with naturalistic subgroup 
based on pattern of medication use as a mediator) may be the source of some confusion about the 
findings of the MTA at the first follow-up. However, the findings based on change scores in the 
secondary article (MTA Cooperative Group, 2004b) converged with the findings based on 
absolute scores in primary article (MTA Cooperative Group, 2004a). Both suggested that the 
persisting but reduced advantage (which also could be called the partial loss of relative 
superiority) of the MTA Medication Algorithm was mediated by the pattern of medication use 
over time. Furthermore, both concluded that the subgroup being treated with medication at the 
follow-up assessment point (i.e., at the time when the ratings of ADHD symptoms were 
provided) had better outcome than the subgroup not being treated. 
b. Evaluation of Stimulant-Related Growth Suppression 
One of the most controversial findings at the first follow-up was from a post hoc analysis 
in the secondary article (MTA Cooperative Group, 2004b), which suggested a possible long-term 
side-effect of treatment with stimulant medication on physical growth. Because the hypothesis of 
stimulant-related growth suppression suggested by Safer et al. (1976) had been largely 
discounted in the years since its original publications (Roche et al., 1979; Spencer et al., 1996; 
see NIH Consensus Conference, 1998), it was not an a priori hypothesis and thus was not 
specified as a primary question to be addressed by the MTA or even evaluated in the initial 
analyses and main report (MTA Cooperative Group, 1999a, 1999b). Thus, post hoc analyses 
were performed to evaluate physical size at the end-of-treatment. Because age and sex were 
balanced across the assigned treatment groups, we used absolute measures of size (cm and kg) 
rather than relative measures of size (z scores) in these analyses. This might be considered a 
weakness by some (see Spencer et al., 1996), but others (see Kraemer et al., 2000) recommend 
the use of raw scores not standardized scores in some situations, such as when the norms used for 
standardization are cross-sectional. Even though growth norms are based on cross-sectional data, 
in the next report on growth in the MTA we used relative measures of size (see Swanson, Elliott, 
et al., 2007). 
The same strategy that we applied for the ADHD outcome measures (see above) was 
used for the analysis of height and weight (i.e., ITT analysis of assigned treatment on change in 
size from baseline to the 14-month end of treatment assessment point). These analyses revealed 
that for the groups assigned to treatments that included the MTA medication algorithm, the 
average gain in height (Comb = 4.85 cm and MedMgt = 4.75 cm) was less than for the other two 
groups (Beh = 6.19 cm and CC = 5.68 cm). The same pattern held for gain in weight (Comb 
= 2.52 kg and MedMgt = 1.64 kg vs. Beh = 4.53 mg and CC = 3.13 kg). Thus, the “gold 
standard” for evidence-based medicine—ITT analysis of an RCT—provided clear evidence of 
stimulant-related growth suppression. For the most informative comparison of the two unimodal 
treatments (MedMgt with assignment of medication and Beh without assignment of medication), 
we observed a reduction of growth velocity by about -1.23 cm/yr in height and -2.48 kg/yr in 
weight at 14 months. These might be considered conservative estimates, because there was 
imperfect acceptance and compliance with assigned treatments, as noted above (see Marcus & 
Gibbons, 2001). 
By the end of the 10-month follow-up, ITT analyses no longer showed a stimulant-related 
growth suppression effect based on a comparison of the assigned groups or the MTA medication 
algorithm comparison (MTA Cooperative Group, 2004b). However, the expected growth 
rebound was not detected by the analysis of 14-month to 24-month change for the assigned 
treatment groups: All assigned groups had about the same gain in height and weight (Comb = 
5.69 cm and 5.28 kg; MedMgt = 5.69 cm and 5.06 kg; Beh = 6.16 cm and 4.98 kg; CC = 5.79 cm 
and 4.58 kg). On the other hand, analysis of actual treatment defined by the naturalistic 
subgroups revealed that a subgroup of consistently treated children (i.e., those on medication at 
both the 14-month and 24-month assessments) relative to an untreated subgroup (i.e., those who 
were not treated with medication at the 14-month or 24-month assessments) showed reduced 
gain in height and weight, which suggested additional stimulant-related growth suppression 
during the first 10-month follow-up period. In the naturalistic subgroups, the apparent effects of 
actual treatment on reduction in annual growth velocity (12-month estimates from the initial 14-
month and subsequent 10-month intervals) was similar for the height reduction documented 
during the treatment phase (-0.9 cm/yr) and follow-up phase (-1.02 cm/yr), but the apparent 
reduction for weight was less in the follow-up phase (-1.22 kg/yr) than documented in the 
treatment phase (-2.55 kg/yr). 
3. Qualification: Loss of Effectiveness or Lack of Maintenance 
a. Partial Loss of Relative Benefits of Medication 
We speculated that the partial loss of relative superiority may have been related to the 
continued use of ITT analyses of the randomized groups even after the assigned treatments were 
no longer provided. In fact, these analyses evaluated the effects of assigned treatments even 
though at the end of the treatment phase we recommended for many cases that the components of 
assigned treatment be changed (i.e., at the 14-month assessment we recommended adding 
medication in 74% of the cases in the Beh group). Also, we speculated that our methods were 
based on relative comparisons of conditions superimposed on a much larger effect of general 
overall improvement over time (i.e., a dramatic reduction in severity of ADHD symptoms), 
making it more difficult to detect positive effects of medication. This speculation was supported 
by supplemental analyses of actual treatment that added a covariate for interim medication use, 
which revealed a significant positive effect of medication on outcome at the 24-month 
assessment—in addition to the smaller but still significant effect of assigned treatment. 
Nonetheless, the main controversy at the first follow-up was about lack of maintenance of 
medication. In the MedMgt and Comb groups, the number of cases continuing medication 
decreased, and we speculated that deterioration in those stopping medication might account for 
some of the apparent loss of effectiveness of these conditions compared to the Beh condition, 
which showed an increase in the number of cases treated with medication. Thus, one aspect of 
this controversy was about changes in actual treatment, which we speculated may operate to 
discredit an effective treatment. We predicted that if the trend of between-group differences in 
starting and stopping medication continued, then the assigned groups would converge in later 
assessments of outcome. This prediction was tested in the evaluation of outcome in the next 
follow-up (see Jensen et al., 2007). 
b. The Main Confusions and Controversies at the First Follow-Up 
Why were these primary findings of the first follow-up controversial? Some children 
(particularly those in the MedMgt and Comb groups) deteriorated during follow-up when the 
assigned treatments were no longer provided by research staff according to the MTA protocols. 
This was reflected in ITT analyses of randomly assigned treatment groups, which suggested that 
the relative benefits of medication were waning over time. This pattern was different than 
expected from other long-term follow-up studies (e.g., see Abikoff et al., 2004), which showed 
persistence of benefits across 2 years of treatment when intensive medication was provided by 
research staff as part of the study’s protocol. 
Also, ITT analyses and secondary analyses of actual treatment appeared to contradict 
some well-established and long-held beliefs about physical size and growth of children with 
ADHD. For example, the MTA data on physical size did not support the generally accepted 
theory of disorder-related rather than treatment-related differences in physical size that 
hypothesized children with ADHD had a “slow tempo” or delay in growth (Spencer et al., 1996). 
In addition, the persistence of growth suppression that appeared to accumulate over 2 years did 
not support the consensus opinion of two blue ribbon panels, which had concluded that long-
term stimulant-related growth suppression was not of significant concern (NIH Consensus 
Conference, 1998; Roche et al., 1979). 
Thus, the analyses at the first follow-up suggested that the balance of benefits and side-
effects was different that earlier reported—with smaller benefits and greater side-effects than 
expected based on prior findings and the literature. 
D. Second Follow-Up (Jensen et al., 2007; Molina et al., 2007; Swanson, Elliott, et al., 2007; 
Swanson, Hinshaw, et al., 2007) 
1. Evidence: ITT and Moderator Analyses 
The analyses of the first follow-up 24 months after randomization (see above) suggested 
that the apparent reduction of the relative effects of stimulant medication may reflect lack of 
maintaining an effective intervention more than reduction in the effects of medication. Even 
though we predicted the convergence of assigned groups by the 36-month assessment (MTA 
Group, 2004b), we expected to account for this by the patterns of long-term maintenance of 
treatment with medication in our analyses of outcomes over this additional time interval. 
As discussed repeatedly above, in the RCT design ITT analyses of assigned treatment are 
evaluated over the long-term even when treatments are no longer provided or have changed. In 
the primary article about the 36- month outcomes, this approach was used again to evaluate 
differences across the assigned treatment groups at the 36-month assessment. Benefiting from 
experience gained from the end-of-treatment and the first follow-up evaluations, we used four of 
the same outcome domains described previously (parent-teacher ratings of ADHD and ODD 
symptoms; social skills rating; reading achievement), plus one additional outcome measure that 
was considered appropriate for the older age of the participants (the Columbia Impairment Scale, 
which replaced the Parental Discipline measure used in the analysis of the first follow-up). Also, 
we used the same three orthogonal comparisons adopted for the 24-month assessment to test for 
persisting relative superiority of the MTA medication algorithm (Comb + MedMgt > Beh + CC), 
as well as for Multimodal Superiority (Comb > MedMgt; Comb > Beh) and for Psychosocial 
Substitution (Beh > CC). 
The ITT analyses show that the assigned groups did not differ significantly on any of the 
five outcome measures (Jensen et al., 2007). The comparison of effect size indicated that the 
large relative superiority of the MTA medication algorithm at the 14-month assessment was 
negligible at the 36-month assessment. That is, despite the large superiority of the medication 
algorithm at 14 months, and its continued presence (though reduced size) at the 24-month 
assessment, by the 36-month assessment there was essentially no difference between those 
participants who were and were not initially randomly assigned to a treatment that included 
intensive medication management according to the MTA protocol. However, it is important to 
note that this effect was superimposed on a very large overall improvement for all of the 
assigned treatment groups (e.g., for the baseline-to-36-month change, the effect sizes estimates 
were from 1.6 to 1.7 across the four treatment groups). Thus, as expected from most longitudinal 
studies in the literature, in the MTA follow-up the severity of ADHD symptoms decreased over 
time, but this was independent of assigned treatment. 
These findings at the 36-month assessment confirmed the prediction stated in the prior 
report (see MTA Cooperative Group, 2004b): The residual relative superiority of the MedMgt 
and Comb treatments over the Beh and CC treatments had completely dissipated by 22 months 
after the end of the treatment phase (Jensen et al., 2007). 
In the primary article, mediator analyses were applied to evaluate possible reasons for the 
complete loss of relative superiority of the MTA medication algorithm (Jensen et al., 2007). 
From the SCAPI, the reports of actual treatment received revealed that there was a 24-36 month 
increase in the percentage of participants using medication in the Beh group (from 34.9% to 
45.2%), but this percentage in the other treatment groups remained nearly constant (see Jensen et 
al., 2007, Table 2: 71.0% to 70.4% for Comb; 71.6% to 71.8% for MedMgt; 62.3% to 62.4% for 
CC: the last dose equivalents listed in the table are averages that include 0 doses for participants 
not treated with medication at the 36-month assessment). Analysis of covariance for ADHD 
symptom severity revealed that actual medication use (percentage of days treated) was 
significant as a main effect and interacted with time. However, the direction of this effect was 
different for the two follow-up intervals: Greater medication use produced better outcome at the 
14-month and 24-month assessment points, but at the 36-month assessment point there was no 
significant mediating effect of medication use for the overall baseline to 36-month follow-up. 
Thus, our prediction that loss of relative superiority would be related to maintenance of treatment 
was not confirmed. Intriguingly, a post hoc analysis of 24-36 month change in symptom severity 
revealed that medication use over this follow-up interval was related to deterioration (increase in 
symptom severity) rather than benefit. 
Also, in the primary article (Jensen et al., 2007) we performed moderator analyses to 
evaluate comorbid anxiety and other subgrouping factors present at baseline as moderators of 
treatment response, but these did not reveal subgroup differences. Thus, the initial enhanced 
response to the Beh treatment in children with comorbid anxiety (see MTA Cooperative Group, 
1999b) was not observed in the long-term follow-up. 
2. Interpretation: Multiple Secondary Articles 
a. Departure From Prior Pattern 
In a departure from our prior strategy of publishing two main papers under the group 
name, we decided that multiple secondary articles were necessary to address possible 
explanation for these findings and to address important additional outcome measures as the 
sample approached adolescence, which required considerable time and effort of working groups 
that should be recognized by naming authors. Also, when using standard methods to search for 
articles published on the MTA, the typical strategies (i.e., author’s names) do not always locate 
or identify the published articles, making a review of the complete literature difficult. 
b. Selection Bias and Individual Differences 
In the primary article by Jensen et al. (2007), exploratory analyses were reported as well 
as the main ITT analyses, which suggested that a small subgroup who had stopped medication 
between 24 and 36 months were doing better at 24 and 36 months than another small subgroup 
who started medication between 24 and 36 months. This seemed to indicate that self-selection 
for medication might explain the apparent lack of relative superiority at 36 months. However, 
these subgroups were small. The results were reported electronically in the Article Plus website, 
and a reference was made to more detailed analyses in the companion article by Swanson, 
Elliott, et al. (2007). 
In the initial secondary article (Swanson, Hinshaw, et al., 2007) we addressed in more 
depth the hypothesis that selection biases might account for the loss of relative superiority of 
medication. If the most severe cases, expected to have poorer outcome than the less severe cases, 
were preferentially treated with medication at the 36-month assessment, then this factor may 
account for its apparent loss of efficacy. The statistical method selected to evaluate this 
hypothesis was the propensity score analysis. This propensity analysis relies on the assumption 
that selection biases can be modeled as a simple linear combination of multiple, complex 
variables, such as ethnicity, previous experience with medication, treatment response, SES, and 
other variables, which may or may not be correct. As described and discussed in Swanson, 
Hinshaw, et al. (2007), a propensity score was created for each participant based on variables 
associated with the tendency to take medication. We used this procedure to test the hypothesis 
that medication use might be associated with both factors—the propensity to take medication and 
to have poor outcome. If present, this association could result in a bias when comparing 
subgroups that were treated and untreated with medication, and could theoretically mask any 
relative superiority of treatment with medication. 
However, counter to our hypothesis, the severity of ADHD symptoms was not related to 
the use of medication at the 36-month assessment: The quintile representing those cases most 
likely to use medication at the 36-month assessment had lower rather than higher ratings of 
ADHD symptoms at the 14 and 24 month assessment points. Also, when subgroups of cases with 
and without actual use of medication were compared across five levels of the propensity score 
(quintiles), there was no evidence of the superiority of actual use of medication in any quintile 
(Swanson, Hinshaw, et al., 2007). Thus, the propensity score analyses did not provide statistical 
support for the basic hypothesis that selection bias explained the lack of a significant medication 
effect in the MTA follow-up. 
Additional analyses of change over time were performed using a statistical procedure 
called growth mixture model (GMM) analysis (see Hedeker & Gibbons, 2006). In this context, 
the use of the word growth does not refer to physical growth but to the trajectory of change over 
time in any outcome measure. As described and discussed in Swanson, Hinshaw, et al. (2007), 
the GMM approach was applied to determine if the trajectory of ADHD symptom severity over 
time was homogeneous across all participants in the MTA follow-up or whether more than one 
trajectory provided a better explanation for change over time. The best fitting model was for 
three latent classes, each with a different pattern of change in ADHD symptoms over time. Class 
1 (34% of the sample) showed an trend of gradual improvement (decrease in ratings of ADHD 
symptom severity) that was small at the 14-month assessment but continued to the 36-month 
assessment. Class 2 (52% of the sample) showed a large improvement at the 14-month 
assessment that was maintained through the 36-month assessment. Class 3 (14% of the sample) 
showed a large initial improvement followed by a trend of deterioration over time that resulted in 
a return to the baseline level of ADHD symptom severity by the 36-month assessment. This is 
consistent with common sense and clinical experience, as it indicates that not all children with 
ADHD are the same and that individual differences in treatment response and development 
should be considered. 
Analyses were performed to examine the possibility of different effects of assigned and 
actual medication use in these three classes. Even though the overall comparisons of subgroups 
with and without consistent medication revealed no overall evidence for the relative superiority 
of medication, the multiple classes from the growth mixture model analysis allowed for within-
class comparisons to test the hypothesis that counteracting effects across the classes might mask 
the relative superiority of medication within certain classes. 
The medication effect was evaluated within each of these latent classes by comparing the 
class members with consistent high use of medication over time to the class members with 
consistent low use of medication. All three latent classes showed a significant relative superiority 
of consistent high use over low use at the 14-month assessment, but for Classes 2 and 3 this 
effect dissipated and was absent by the 36-month assessment (i.e., the same pattern reported by 
Jensen et al., 2007). However, for Class 1, the relative superiority of medication (defined by 
consistent high vs. low medication use) was significant at the 14-month assessment (p = .041), 
and it became larger and was still significant at p = .001 at the 36-month assessment. This pattern 
suggests not only maintenance of the medication effect but an increase in its magnitude over 
time. Because this pattern was present in a minority of the cases (34% of the sample in this 
class), it was masked in the primary analyses by the opposite pattern in the majority of cases 
(i.e., a large initial relative superiority of medication that dissipated over time in the 66% in the 
two classes comprising a majority of the sample). The analysis of the baseline measures showed 
that Class 2 differed from both Class 1 and 3 but there was no clear distinction between 1 and 3. 
The participants in these two classes had patterns of high scores that indicated much greater 
adversity on demographic measures and severity on symptom measures than the participants in 
Class 2. 
Also, the most favorable trajectory (shown by Class 2) had a preponderance of children 
originally assigned to treatment with the MTA medication algorithm (62% of the Comb and 55% 
of the MedMgt, for a total of n = 169, vs. 46% of the Beh and 45% of the CC, for a total of n 
= 129), which suggested a possible residual benefit in some cases even when actual medication 
use had stopped. 
c. Stimulant-Related Growth Suppression 
The third article focused on the hypothesis of stimulant-related growth suppression 
(Swanson, Elliott, et al., 2007). Based on the surprising finding of stimulant-related growth 
suppression uncovered by post hoc analyses in the second main report (MTA Cooperative 
Group, 2004b), we continued our analyses of physical growth. For the analyses of the data 
through the 36-month assessment point, we improved our methods. In emerging naturalistic 
subgroups based on treatment choice at each successive assessment point, we identified 
individuals who were never, newly, consistently, or inconsistently treated with medication. We 
performed more sophisticated analyses of height and weight by using standard scores based on 
national growth norms (z height and z weight) as the outcome measures, rather than absolute 
height and weight as in the prior analysis. 
In the regression analyses, the interaction of naturalistic subgroup with time was 
significant for both height and weight. This provided the statistical support for the hypothesis 
that the pattern of treatment with stimulant medication was associated with the growth velocity 
over time. We reported a surprising pattern of growth in the participants never treated with 
medication (i.e., an untreated clinical control group). Compared to population norms, this group 
was physically much larger than expected from U.S. norms (or by comparison to classmates in 
our own local normative comparison group consisting of classmates of the ADHD participants). 
Also, this never-treated subgroup showed growth acceleration (an increase in z scores) over time. 
In contrast, the newly treated subgroup (initially stimulant-naïve but then consistently treated 
after entering the MTA) showed growth suppression (a decrease in z score). The magnitude of 
the difference in growth between these two diverging groups over the 36-month follow-up was 
about 2 cm, which occurred during the first 24 months and then stabilized, with no recovery (i.e., 
no growth rebound) but with no additional growth suppression either. Whether stimulant-related 
growth suppression is permanent or will be made up at the end of the growth cycle is a question 
to be answered by future analyses of data from the 12-year assessment when the participants will 
be between 19 and 21 years of age. 
In the formation of naturalistic subgroups at this point in the follow-up, we took into 
consideration prior history of medication to form the naturalistic subgroups. Even though this 
was very limited information (i.e., report of use of medication within 30 days prior to the 
baseline assessment), our analyses revealed an interesting finding: The subgroup treated with 
medication prior to entry into the MTA and then consistently treated with medication in the 
MTA protocol were physically much smaller at baseline than the other naturalistic subgroups. It 
is possible that prior treatment with medication resulted in this difference. However, these 
naturalistic subgroups were not established by randomization, so it is also possible that a 
selection bias was present, and the smallest ADHD participants in the MTA were selectively 
treated with medication at an early age. 
d. Delinquency and Substance Use 
The fourth article focused on a new set of outcome measures (Molina et al., 2007). With 
adolescence impending by the 36-month follow-up, we analyzed severity of delinquent behavior 
and substance use (Molina et al., 2007). Delinquent behavior was coded along a 5-point 
continuum of severity using several parent- and child-reported measures. Twenty-seven percent 
of the children had engaged in moderate-to-serious delinquent behaviors by the 36-month 
follow-up, and these rates were not affected by original randomized treatment group assignment. 
They were significantly higher than the mostly non-ADHD classmate comparison group called 
the Local Normative Comparison Group (p < .0001). Not surprisingly, children with higher 
delinquency scores were more likely to be medicated at follow-up. 
For these analyses, substance use was defined as any use of alcohol (more than a sip), 
tobacco, or marijuana. The observed rates of endorsement were significantly higher among the 
MTA participants compared to the LNCG participants (classmates of the ADHD children). 
Counter to the predictions in the literature (see Biederman, Wilens, Mick, Spencer, & Faraone, 
1999; Wilens et al., 2003), the participants in the MTA who were treated at a young age with 
medication did not show any evidence of protection from initial use of substances in our 36-
month analyses. Instead, receipt of behavioral therapy was associated with some protection. At 
the 24-month assessment, the children who received behavioral therapy (Beh or Comb) were less 
likely to report substance use than the children who did not (MedMgt and CC). This effect was 
not significant at the 36-month assessment, but the direction of the difference still favored the 
groups assigned to receive behavioral algorithm of the MTA. These results do not rule out the 
potential for long-term protective or predisposing associations between treatment and later 
substance use, abuse, or dependence that emerge at older ages. Thus, further analyses are crucial 
as the children mature through adolescence into early adulthood when rates of substance use, 
abuse, and dependence reach their peak. 
3. Qualification: Challenging Consensus Views and New Predictions 
a. The Main Confusions and Controversies at the Second Follow-Up 
The findings of these secondary articles were not consistent with views and expectations 
about medication effects held by many investigators and clinicians in the field. That is, long-term 
benefits from consistent treatment were not documented; selection bias did not account for the 
loss of relative superiority of medication over time; there was no evidence for “catch-up” 
growth; and early treatment with medication did not protect against later adverse outcomes. It is 
likely that these challenges to consensus views contributed to confusion and controversy about 
the long-term outcomes in the MTA. 
Why were these primary and secondary findings at the second follow-up controversial? 
The intent-to-treat analyses suggested that the modest significant advantages we found at the 24-
month assessment for the MTA Medication Algorithm were completely lost by the 36-month 
assessment. Because this was predicted from the findings at the end of the first follow-up (MTA 
Group, 2004b), this was not unexpected or controversial. However, counter to our prediction, 
when actual treatment with medication was evaluated, the subgroup with current treatment 
(compared to the subgroup without) showed a tendency toward disadvantage rather than the 
benefit. This may be the primary reason for controversy at this point in time. 
However, we found no support for the hypothesis that selection biases were “carrying” 
this lack of long-term benefit from medication—even though we used a sophisticated method 
(propensity score analysis). This method had previously uncovered a participation bias during 
the treatment phase of the MTA, which was found to affect outcome at the 14-month assessment 
(Marcus & Gibbons, 2001), but when applied to the long-term follow-up phase, this method did 
not confirm our predictions (see Swanson, Hinshaw, et al., 2007). 
Also, based on the literature, we expected that initial growth suppression might be 
followed by growth rebound, but by the 36-month assessment this pattern had not occurred 
(Swanson, Elliott, et al., 2007). Still, the initial growth suppression had abated by 36 months, 
even in consistently medicated youth. Additionally, one strong rationale for the use of stimulant 
medication was the expectation that this would offer protection against the emergence of 
substance use or juvenile delinquency, but no evidence to support this hypothesis emerged from 
the MTA by this point in the follow-up (Molina et al., 2007). 
The intention and primary value of research is to discover new knowledge, but when new 
findings contradict consensus views, confusion and controversy should be expected. This has 
occurred as we have published the findings of each phase of the MTA so far. It is likely to 
continue in the future as the follow-up continues and new discoveries are made and 
disseminated. 
b. Subsequent Publications of Multimodal Treatment Studies 
Two articles describing effectiveness studies in Europe have addressed some of the 
critiques and predictions from the MTA efficacy study: Dopfner et al. (2004) and van der Oord 
et al. (2007). 
In a study conducted in Germany, Dopfner et al. (2004) addressed the issues of ecological 
validity by using an adaptive design for an effectiveness study of treatment strategies similar to 
clinical practice. A sample of 75 children with diagnoses of ADHD were randomized to 
behavioral intervention (which was purposely less intensive that the Beh condition of the MTA, 
which was estimated to be about three times as intensive) or to medication management (which 
was also purposely less intensive than MedMgt in the MTA, which was estimated to be about 
two times as intensive). The disposition of the sample was dependent on acceptance of 
randomization (which was low for assignment to treatment with medication) and response 
(components were stopped or started dependent on outcomes at four stages of the study). 
Outcome was evaluated by using change from baseline as an indication of improvement. At the 
end of treatment, the resulting adaptive multimodal treatment produced a success rate of 55% 
(compared to 68% for the MTA). Part of the difference was attributed to differences in intensity 
of treatment components, which was estimated to be about half as intensive as the 
pharmacological component of the MTA and one third as intensive as the psychosocial 
component of the MTA. Adjusted for intensity of intervention, these outcomes suggest similarity 
with one of the main MTA findings (a slight multimodal superiority despite a lower dose of 
medication), but with a more ecologically valid set of interventions that were less intensive and 
expensive. 
In a study conducted in the Netherlands, van der Oord et al. (2007) addressed the issue of 
differential intensity of the medication component of the MTA Comb and MedMgt conditions. 
They evaluated 50 children with ADHD whose medication was titrated using a procedure similar 
to the MTA double-blind titration trial, and randomly assigned them to receive a 10-week 
behavior therapy (or not). This defined two groups with multimodal (medication plus behavior 
therapy) and unimodal (medication only) treatments. The dose of methylphenidate was lower 
than in the MTA (20.8 mg/day) and the placebo response rate was higher (41%). The intensity of 
behavior therapy was designed to be less than in the MTA in order to match psychosocial 
intervention that was practical and available. The outcomes at the end of the 10-week treatment 
phase showed no difference between the two groups in multiple measures of outcome designed 
to evaluate symptoms as well as global functioning. The findings from this effectiveness study 
are consistent with the findings from the MTA efficacy study, and produced estimates of effect 
size that were comparable. However, the findings from this effectiveness study should be 
interpreted with the same cautions recommended here for the interpretation of the findings from 
the MTA, with special caution about acceptance of the null hypothesis. 
E. Clinical Relevance 
1. Questions and Interim Answers 
What do the findings from the MTA offer to clinicians and parents who seek answers to 
key questions about long-term effects of stimulant medication? Taken together, the primary 
publications of the MTA provide evidence to answer the following questions. 
a. What is the first-line treatment for initiating treatment of children with confirmed diagnoses of 
ADHD-Combined Type? 
Over the 14-month treatment phase of the MTA, intensive management of stimulant 
medication by the MTA medication algorithm, with or without concurrent behavior 
modification, provided relative superiority compared to the treatments without this component, 
at least for the outcome domains related to ADHD and ODD symptom severity. Thus, the 
evidence from the MTA supports this regime as the first-line treatment (MTA Cooperative 
Group, 1999a). 
b. Does childhood treatment with stimulant medication produce a clinically meaningful 
reduction in growth? 
Stimulant-related growth suppression (about a 20% reduction in annual gain in height) 
was documented by the gold standard—an intent-to-treat analysis at the end of treatment. 
Exploratory mediator analyses suggested this effect may accumulate over 2 years to reduce 
height gain by about 2 cm in children receiving consistent medication, but no further increase in 
(or rebound from) height suppression occurred in those children remaining on medication for an 
additional year. However, this may not be a permanent reduction in physical size, as catchup or 
rebound growth could still be possible in the MTA sample, which was only 10 to 12 years of age 
at the time of the 36-month assessment. 
c. Is the relative superiority of the MTA medication algorithm a long-term effect? 
A fundamental purpose of the MTA was to provide evidence about long-term effects. 
Long-term relative benefits of stimulant medication were documented and appeared to remain 
constant in the early, middle, and end of the treatment phase of the randomized clinical trial (i.e., 
at the 3-, 9-, and 14-month assessments). Therefore, when long-term is defined as up to 2 years, 
the MTA findings provide evidence of a long-term relative benefit of the initiation of treatment 
with the MTA medication algorithm (MTA Cooperative Group, 1999a, 2004a). However, if the 
definition of long-term is extended to 3 years, the relative superiority appears to be lost, so this 
benefit does not seem to be a permanent and thus could be considered a temporary effect (Jensen 
et al., 2007; Swanson, Elliott, et al., 2007; Swanson, Hinshaw, et al., 2007). 
d. Does the relative superiority last as long as the treatment is maintained? 
Despite a relatively high rate of medication use (70%), the relative superiority of having 
experienced the MTA medication algorithm was negligible and nonsignificant by the 3rd year of 
the study (Jensen et al., 2007). Current medication use did not account for this loss of relative 
benefit. Therefore, the accumulated evidence at this point in the series of reports of outcomes in 
the MTA suggests that the relative superiority of medication may be temporary for the majority 
even when treatment is continued, although it may continue to be increasingly effective for about 
one third of such children. It is possible that this loss may be due to how the treatment is 
managed in the community setting, which may be very different than management according to 
the MTA algorithm (i.e., with regular monthly visits to obtain information from parents, 
teachers, and the child and to make medication adjustments on the basis of this close monitoring 
of compliance and outcomes). 
e. Does the selective treatment of the most difficult cases mask the beneficial effects of stimulant 
medication? 
The hypothesis of selection bias was not supported when rigorously tested by applying 
propensity score analysis (Swanson, Hinshaw, et al., 2007). Although the preponderance of 
evidence so far from the MTA does not suggest that the loss of relative superiority was an 
artifact of comparison of biased subgroups, it remains plausible that some bias not yet evaluated 
may be present. We are still considering exploratory analyses of differences in outcome based on 
who is treated (determined by self-selection as individuals choose to maintain, stop, or start 
medication) and how they are treated (determined by community practitioners who may not 
continue the close monitoring and adjustment of medication). It is clear that additional studies 
are needed to characterize who starts and who stops treatment with medication, and for what 
reasons, during the course of long-term treatment. 
f. Do some identifiable subgroups benefit from one treatment (either pharmacological or 
psychosocial) more than other subgroups? 
The end-of-treatment moderator analyses generated hypotheses that anxiety and 
socioeconomic status may identify subgroups with enhanced response to behavior therapy, but 
this was not confirmed in the follow-up analyses. However, growth mixture model analyses of 
outcome through the 36-month assessment provided another way to form subgroups based on 
different outcome trajectories. One subgroup (34% of the participants) showed modest but 
monotonic improvement over time. In this subgroup, those consistently treated with medication 
compared to those not treated show significant initial benefit that increases over the 3 years of 
treatment (Swanson, Hinshaw, et al., 2007). However, analyses of MTA baseline measures did 
not reveal how to predict membership in this subgroup in advance, so the empirical approach of 
monitoring response over time is necessary to identify this subgroup. 
2. Practical Suggestions and Future Directions 
The initial findings of the MTA at the 14-month assessment (MTA Cooperative Group, 
1999) clearly show long-term benefits of the stimulant medication for longer than 1 year, 
addressing a fundamental question that of the MTA. These findings were important, because at 
the time there was little information in the literature on the long-term effects of stimulants. Prior 
to the MTA, many published studies had documented short-term beneficial effects over a few 
hours, a few days, a few weeks, or a few months. The MTA articles added to the literature by 
extending the evaluation to the long-term—defined initially as a little longer than a year, when 
clear benefits were present. 
The findings from the first follow-up (MTA Cooperative Group, 2004a, 2004b), which 
documented partial persistence of the relative superiority of the MTA medication algorithm, 
provided another contribution to the sparse literature on long-term effects of medication. The 
partial loss of effect must be interpreted in light of maintenance of treatment, which was reduced 
in the transition to treatment as usual in the community. Another long-term treatment study 
(Abikoff et al., 2004) showed continued full benefit for 2 years when treatment was monitored 
and adjustments were made to the medication regime over the entire time period. 
The findings from the longer term follow-up (Jensen et al., 2007; Molina et al., 2007; 
Swanson, Elliott, et al., 2007; Swanson, Hinshaw, et al., 2007) provide additional guidance for 
evidence-based treatment that do not contradict the initial findings but do provide a new 
perspective. These additional findings suggest the possibility that the relative superiority of the 
intensive, carefully monitored medication management gradually dissipates when the children 
are returned to community treatment, and the longer term relative benefits are not apparent even 
when compared to children who are never treated with stimulant medication. 
However, because the MTA outcomes are based on averages across individual children, it 
is likely that the relative superiority of medication will not dissipate in all cases, so 
individualization of long-term treatment guided by evaluation of withdrawal of medication 
makes sense. 
Despite the challenges of integrating controversial findings into prior literature and 
practice, continued follow-up of the MTA participants could provide answers to a number of 
important questions. We have presented the outcomes at the 8-year follow-up (MTA Research 
Symposium, 2007), and the 10-year follow-up has been completed. The 12-year follow-up is 
now in progress. In the future, based on additional information from the MTA follow-up, we 
expect to address many new questions, including questions about access to services for children 
with ADHD, particularly for families seeking high-quality mental health treatment; about 
ultimate attainment of height and weight for children who show initial stimulant-related growth 
suppression; and about other long-term symptomatic and functional outcomes associated with 
ADHD. 
In conclusion, the MTA continues to provide information that is both clinically relevant 
and intellectually stimulating. It is still providing evidence about long-term effects of treatment, 
generating interest in pertinent issues related to the long-term course of ADHD, and setting 
directions for future investigations. It will be crucial to examine further patterns of treatment-
related effects during the current 12-year follow-up of participants in the MTA that is now in 
progress. 
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